Insertion of Rule 122DAB, Appendix… Bare Act

The source publishes this enactment as a single document rather than provision by provision, so the whole text is below and there are no per-section pages for it. Nothing has been shortened.

Type	Notification
Year	1940
Jurisdiction	Central
Ministry	Ministry of Health and Family Welfare
Status	In force as published by the source
Text	Published as one document, as the source published it
Subjects	health, social

tf^F# "STo ^ o T ^ I O - 3 3 0 0 4 / 9 9 JO^^C^ REGD. NO. D. L.-33004/99 (The <5azette of <3tidia EXTRAORDINARY *n*T II—*SP*5 3—:3T-<flUS (i)

PART II—Section 3—Sub-section (i) •Biftranr % W*IR>M PUBLISHED BY AUTHORITY K 47] ^ 1 ^ # , ^ s r a i T , ^ r a f l ' 30, 2013/ura-10,1934 No. 471 NEW DELHI, WEDNESDAY, JANUARY 30, 2013/MAGHA 10, 1934 1 wifvwj afrc Mfam *<rui«i tii\m 3tf&W£eMI ^ f e # , 30 "SR f̂t, 2013 w.w.fa. 53(3T).—3TW«T 3 ^ 3rai«R wnft fvm, 1945 >̂T 3*R "*f#«R ^ ^ ^ farj +Rim f=praf ^ 3n?^ sfafa 3?R W ^ W ^ 3 T f a t W T , 1940 (1940 >̂T 23) *ft 3RT33 ^ M * ! 9RT12 ^ft artwjfflT, *TM^IF3ro^, 3raTORT, <qm II, 13S 3, "ST-WS ( i ) , <TRR9 18 H*IH<, 2011 f̂, 1TO *K+K ^ ^R**T 3?R <ffolR 3F»<rTT«l WSn?W (^ l**4faMm) ^»t STfiRJ^n « W + m ^ f t . 821(3T),:cTRn3 18 H ^ * , 2011 jJRT M*l(VW 1*FTT̂ FTI «TIf̂ PST̂ *"3̂ T̂*ft «lfckwT^, frH.^l "3*R}"SRlf^tTFR ^ftwmfkl ^ ^ 3fI8̂ T 3?R '̂ 5?ra "HPT "m, $;

31R <NM^ t̂.TITlPCT f̂RrlT «Ff 24 -1*I»«R, 2011 ^f <Wd<*T <TO ^t ^ *ff;

3tR 33<T TWTT TT *R<IT « W% 3Twtf SIR ^ 1 3 1 Vt # 1 W*T7 ^ T^TR ^T MTT ¥ ;

3m:, SRI, <&?h WftK, s fa fa 3 ? R T R P R « t 3#rf%*W, 1940 (1940 ^T 23) 3JT *TKT12 3TR **RT33 gRT3P^T VlPtd̂ T T̂T 3rqRi ^R^ F^, sfrqftr <rwfl«l Uciie+K *rte ̂ v̂ wvf ^R^ «£ ws^ sfNfa sfa W F T uwii) m*re, 1945 ^T sfk "H^^n «f^ ^ f^ RnRriRsiti 'Ppm ^ m t t , 3T»^ : -

1. (1) ^ t̂ nm s?hfi S?R TrerrsR ̂ roft (tm^n •#?it«rT) fwr, 2013^1

(2) ^ TR4^ "̂f " 3 ^ H«t)|!)H ^ TIRNr ̂ TT̂rT FF\ I z sfhftr 3?R 3Rn«R Trmrft iwr , 1945 (f3R} | ^ f ^ ^ 4!J^I^3^f 1WT "3JST TfRT t ) f̂,—

(i) ~35f\ f^m"#, 1WT 122 ^^Pi> ~% 4JMÎ (HHrdRsifi 1WT 3m*^«nPm%qi"an^Tn, 3T«rm,:— " 122. T̂ ̂ ŝf - ^ l f l * TRfeFT ^ ^RB ^M IT *[rg ^ft l^rra "̂ f TlfcT »̂T,— ( 1 ) l̂pT<fc 'tRT̂ n'T T̂T̂ o^Hw ^fr 8jm ^ ^W *̂, 3 ^ , ^IFf cW 3T f̂8rm F, f^:^^> r^i+rHI •JRftR TP̂ R %^1

(2) " ^ "tRr̂ miefR oqflm ^t F R =IMT asm ^IPM+ "q^^Fi "̂ "̂ M m̂ t , ^ ^tn •sqfar fwr 21 ^ "srs (^) ^ 3T«fN MR"Hlft(1 3 ) ^ i m UlftaiRT ^ 3T1̂ ?T ^ 3T3?1R faifto wld<*< ^ #f^ *ft S+^K FFTT sfk TWtfk n(fl<*)i 419 GI/2013 (i) 2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(i)] f?Kr 3fr I ^ T T ?Ur aftr ftrfm yid+< ô rfrFr ^ Rfor^ i srasw qr S^^TH f ^ t szrat tf 3TfdfW 3fTT IFTC FTTT I

(3) £31% # 3 ^ ^t ?rat?IcT ^ d l P l * H0^u l # ^TT #, 3:?WT / 33T# <HI<Hft£Rlcfl, f^RT. 21 & 33S (13) ^ 31$m MRSHir̂ H 3^?TN3T Ulf?l*|{l % 3fl£$r 3i 3^OTT fM*T yfa^T <£T F^TR FTJTT 3ftr T t̂fra" yfd<M W 03% % RlfooHi sratw qr 3^?^ 3 ^ fatfr c2T?r #T artMtP sfa 3if?RT FT?TT!

{4) MflWull*TM cJrf?*> ^ 3dl1^+ tF t̂aror, eTfrt T̂T 3Jr^ * t 5T9IT 3T Rfa>oHI q^tW 3fk f ^ f SfcfaR <TT 03TJT, ^ T t ^ qfTSTUT % WT^oi* 5RT ̂ F5* ftiill diyJII f

(5) Pu-nfafSd +Kuii £ ^<iiQ+ irftem A FT^ 3i<4t czrf?fi # £rf?r m sj^g £r Ŝ TT ^T arfcT I T *foj # *raflja" StetPw qtrsror ^T ^q- JT ^wpr ^HJJII 3tk ^rsnf^trfct &&$ *rr 3*wr / J H # «HwPi5f^ft Wr arid" r̂r 3 ^ #r fair tM*r yfd"*^ % F 2 ^ FW":

OF) 3V<^u|lc<H+ 3FRTS (JcMldfl) F̂T yfd<fc<H W I CO") 3J<3<Hlfcd oHiTlTjT̂ ^T 3lfd*<H"1, 3dlPl+ +4MH 3T«mr «wW*> 2TT 3 ^ yfdfaf*} 3TT a r ^ q ^ 5Ri 3^rr I (T) 3TRlf5tH txft^rfRT qSTra" q^W ^^T # WZ 3 ? ^ ^T f̂ PpRTT I (*D tw-affw (miRWi) fa^'ftd qtteruT *t tssr-affotr 3^fr?r JF^TT I

(3) 3I«J<Hlfed <H-NMK % 3TPT % ^T #, 31 Pleiad: ĉ aHTST ZTR^ 3W^f3d *R# | ^ UF^dl (xT) ^<ilP)=b qfrSTCT 3T HF-fqdT ^ ^NH<ilO % *BR^ TOT*3T t?^J 5?T F^T 3T^t fiTTd" % f ^ I (!5) 3ft2Rr?r 3T a i d ^ d ^ r f ^<iiP+ q$t$p*r ufsĥ tnJ I

(6) ui^ot* ^ arsrsfr g^rft ?t 3rr ^ wF?rr t^piw 21 #> ss {^) # MR^if^d J ^ I M H 3TfU^ltt # <3<ilPl* ^TfFT 3Î ?TT #T tcTtT, 3Tft^T ^ T̂W SfffT 3IT 3TjF5 ̂ ^ ^ ^ 52l^P y ^ * < ^r $4>t,u F, ^r ^Hwftlrr ^<iPi* qftrŝ nr ^r 5 r̂r ̂ r yfd«t"t ^TST ^ ^ ^ f?ru" ^ ^ER^IT ^rr I

(7) 3f£ yRiT̂ "5R EJTRK ^r {flt̂ r % toTu t^rf^FW y ^ w yEfw 3^3" ^ ar^*H f̂FTTT F 3frr / ?TT arf̂ r ^ jrsiffTa" ^ I P I ^ q^TfFr #T f ^ r yflmunifcT oqtrP * t tM^r yf?i+< m ^rfrp ^r J=R^ ̂ r craftier ^teifSt* yterw ^r ^?rr A szrfrp #T srFit?tc5t?TctT (srrJTt^flrrcrzft) ^r r t̂ftsr yfd*<, 31^14<H yifl3=hl-n f r f ^ d ^T 3T'TJSFT 3TT̂ T 5RT 5^WT ^R°T 3cW 3TT̂ t W 3raW %A % 3T3" ÊTT 3TT̂?T *RfT ^?T mt^rr t^TT 3TRT ^tf^, ^5lPl+ qfr8TUT Plofft'r? 3TTT T£ ̂ T T̂ŴTT ^ 3frT / in m^d<fr ^r ^?T ST ^ 3tk ^ i ts r^ T tow r̂arfpf?r g^r #r f^nr 37T% wTriPif̂ r (yfdPRr^rt) tffFH" fM?T?r ^T ^^r(T F TT ̂ l f 3T??T ^TT5lf ^T ^ i H I ?• 5lt 3TF ?̂ T t̂TSTJTt #T 3TftT5T & F ?3Tifr I (H) 3Wi tSramt 7T ^ I P I + qfRfrw r̂ mftte 3\«^\ n$> *bj (2) A - I I H U H * 1 " >• » i > l"i <|M>i l i>i i 1 I >l ' - « ' I 1.1 i i y i J H H I I I I i l>:>li«|>li I,' . « | B > l i a i a i p • • H > I K * Hill I IHnnl . iUMI |H»l ia* t« «" [••sqpT n—^5 3(i)] *irof ^r TTspre : arai«nr°i (g>) yrato^r fc jcuaiRlw # *raf§H 3q% (2),-

(i) ^ (iv) # Pt^H^fiSd Tm s n w , 3T*fcr > «<iv) tetfaf ^twor # ffl̂ . weft ^F5 *r a M r f r f c ^ u&n *r ^ M t , *TFtr* Q^qui cp^r % q^i?t nnftoi* SRT arraR *rf?rf?r'% 3rt2rcr aiR *TRRTB- 12 fcanto T?RTJT 2i*r * srfR ^timRwftd a^a im yrflmft SRT *rfor ssr tfSrffr *r 3Tt*rer f̂r 3^TR5T wftr̂ RY *r IWfc £r t ^ iat?r * «m 3fk 3¥ tfeiR % HZRST, STST Jjrg £r ataflT y t^cT «JC5TT fc tf* % 5*T ft=T fr 3fmr qt^JT {UH^d felT TOT & arflftcT *T arctfT 1 3JF5 * Siffsr îafrr sricr^r S^TT *r 1H£ ^ R T ^ fa&m * R * * q*TRr MIOWO SRT a^a im srfterX arrnir tf5rf?r * amrer aftr FSSTOT * *rg& agr »iafrr otir^cT SJOTT * ^ r * SRT *<fer ftstt * sftR q f lm ^rrm?T t^rr TOT I, artftjr *r ŝmrafT I" Ca) « s (iv) #r q^icf fo^fa^d aicTî irPlH' ftmr orrw.artfcp- "(v) eajfip * JfciftH. t^iRW ^ ^ g r ^ 8 ^ c r O T 3 j F 5 # ^ r F ^ urarsrar (g* ap ?r^r ^ T T 3ftr qftf̂ TF 12 * wim* m # flfft *rr 3 ^ *r wWJcT ^ r f ^ tSran̂ T * fair rMw tfcm S S R ^r r r 1

(vi) mtm* ( ^ w i i i ^Hf i*^ * ^ ^ *"" ^ ^ ^ ^ ^ 3 * * r ^ ^ . ^ F ^ H ^ t r r ^ ftrjTFT #T f?nr ^r?r OT W& sricRvr % »(lt ^FgfT g*rr l" PO 3i^w(^r) * .idc^cd r̂ r̂aHJrr 3*1% (3) #,-

(i) 3q% "(S)" ^T "(3)(i)" % ^ ^ «HMift.d ftmr m̂iTTT;

(ii) & VT̂ R ^Wiftcf W5 (i) #, "^TSW 24 HT5t * 3tmr 3frT3TreTT ^ t ? T ^T RW* 3 ^ qftcT ^ T #r 7 JSP* t ^ B t ^ 3flHT 3 ^ ^ R ^ftet^T ^T 3^jf>^T feOT JPff t ^t," ?r^, 3 ^ afrr ^re^r * w«r, T*IR *H "Ptw 21 * ^ (a) * 3*ter qHart̂ T 3 ^ ^ sift**, ?TRit5r̂ OT 3^r yf?«3ift Rra^ iferf^ ^^7^ * ?raT̂ T * f?rc 3 ^ i m grf^rtt F 3*3*r m *r «Jt, 3frr anw «1*ri?r f3ra^ 35^ ^ r * ^MRT ** ^ H T trCTT r̂ fW»t 3 i ^ ^ SRT 3rraR rfm * 3r«rer 3ftr ar^rtR art^rtt ^t Wrt *r iw y£t >̂ T̂W qfttttff 12 * 3*fr* at̂ rmsr wtU^t SRT *rfor 5W ^3rt^ * 3T«rer 3frr 3F ^RT^T » srqpir, r̂gt 3 ^ #r ^T^rr^oT q^r » qfer gtt* ^T ^ B T t̂ r• » î tar qfUm ^xji^d^^i ^rr *rr, 3T#*T *r r̂rrpfr I ^ * fte* *ftr ^ r ^ r g^T^lMt ^ R ^ m^T ^ * T O l 3^TW Vnl̂ RY SRT 3TMT Ttf^ * 3T«Taj ^rgr ft* * mar q t m *txnf?rcT R a i r > w r r r T C 1 » * * w * a n * THE GAZETTE OF INDIA : EXTRAORDINARY [pART I I _ S B

(iii) wn ^ R -H^ifod a? (i) % ITOICT Q ^ ^ d m afcmrfaT fcair SITCTTT, arafaj- "(ii) a i ^ i * , ^ i P l * qfternr #f 3TT^3I^r Hrcfr & «rft # qftftlB" v # 3TO7 3^1?^T ^jffcl •np*itH q f^ i r #r wtsw £ c3f% % 3<iiP!+ qfeFT afrr $rf?r 4T 3303 ^r ?raf!̂ T qftsrur # ĝ TT # c3Tf^ 3? ytd<M 5Tcfr ^ ^T ^ 3 r f t ^K & sf t # Ĵ€RT yc^T S ^ I ^ , c3jf?P 3JT j e % <nwPi£Rtfr Hi-HpiSRifd-yr) ^r wi-uld* m 3 ^ yfcPirer £ sq& * R ^ ^T 3*% 3it?J^Rt * si t # aft ̂ m ^m f^re* s£t *TT JJFJ £ OTRJCT *rttePT #r ^ i r # gicfr ^r *T *ft;"

(ST) 3TTETR «f5rtlr % JtRdlRlrfl £ WJRlcT &3 (5) #, 3TO? (iii) ^ q̂ TRT ft<MRlftad "(iv) ^ciPt* q ^ w ^ Ezrfr̂ ^r 3f3ftr «^I«JJH 33?^ $ 3n^ s£r S?TT # airaR ^=i1d U^TT qr 3N5fr ftqtt *T3^F fa&m * q ? w factor qfcft^, qfr silf & ofr V\AU<*> m sew wfciPif̂ r, f^m^r ^ i f t + qftaw &• «CIM<H % fox?" f5^w 21 (a) fc auft^ yftiHiRd aisprffr Hift+ifl £ 3^rf?r qp^r f^rr £, SRT ^ r r #aft ^ arq^r wi % ?nw qftf$T^ 12 * stfm 3i^flW 5Tftm>rtr SRT Jifer 3fran f̂Srf̂ r ^ afE r̂er ^r jfsfk yfd^a ETCSTT #T 21 jRftr yfrî oT U ?̂TT # ŝ rr ^ 3mnr îf*rt?r tre^r qr 3rq^r fttitt w*tt fa^m % q?̂ n?r 3T̂ ?rf?r MiiU+iH t 3^ri?r OTRT ^r ^, SRT ^ a - ^tafri 3i^rrf?r mfa^ifl ^r ^falrr yfd^d Ĉ̂ TT ^ ^ 21 %^3T fef #r lff?R 3TO7TTft?T ^WT|" (?) 3? % (5) ^ qTEITH" PU^Hf^rSd 3icT:PJTfqfT t^ IF 3ITW 3T«fF?[:

"5{3T). Jf3frr yfd^tH ETCSTT

(1) u^- jtafR: yfd^H TO?TT ^( i i f t * q ^ fw % efkR 35F5 ^r wsfiJcT ^ r artq r̂ Rfootfn TO*! I" oit TWT % sraT-̂ rar (5T?r ^ t r qr *T*n1pTd 3it2Rw ^r g îr ^"), ?rt s^-^nr (atH^r M r qr ^ i f a d 3a"?PR ^r S^IT ^) , A R̂TICTTT ^n 3it?rc3ra^ f?r:?raTTrn" r̂r

(2) 3f^rer wtr 3f3ftr ath" 3?q??ntfTH tf?fc£?r ^ ^ 3 ^ * r ftq>t ISfmr 21 ^ ^ 5 (®) * 3^tfR 7TSTT qftWTf̂ cT 3 I<^J1^ y|f?3*||| <£[ gilfl jH* iJT 3^WT MfdPlRJ foTfl^r ?felt^7 qfteiw ^ t?rcr ar^^iffi qrf?j^rfr $ 3^37^ qî fT f l?^ ^ aftr 3TRITT ^ffifd j^ra^ 3^7^R <H<UNK ^F 3 ^ ? ^ T afS^oT f^IT ^ ^T q W ! ^ 11 *• 3T^TTT 3 ^ ErfeT ^ * 24 ^ r #r afrar ^rr i afrr 3^?T mi^ch^ qftt^e: 12 *r 3rtfr?r f ^ r q l ^ r ^ 3*5HTT STf̂ T 3TT 3Jr^ #̂ 3 ^ ^ ^cfyiRd ^?TT 3frf ^ffT 3TT̂ 9̂ T̂ ^F^T 3TT^7 qrf^T ^ T T I " ( i i i )qf t f^T 5 3t, [*nrr i i _^ ros 3(i)] 1(mfT WJT TF5W?t : s^mmr (^) SOT -Hfe-qk. 1 #, 3*r 3R r̂ear̂ F 1.1 #, JTST *n5*iT 9 # gfafM *r ^ I R qr f^^Hfpinad TOT 3!TtJ3TT, 3ttfrcT:

"(9) farcffer gf?r̂ T aftr fifodjtfn sratr * V R ^r farr^ P I ^ I ^ K £:

(^) Jteift* q f l m # sq% cf?r fatfr strict % ^ R *r ^ i r A W ezrffc ^ sw H F̂ artf§R 5J- R:?JC*F factor sratr g^R ftnir snwi faRR 3 R ^ w t a f r # ^4 IH+ * r f l m ^M<H ^ feftr 3R/TR OI^T fam & Sri?T m 3JF^ $> fcfiT faccti^ 3RERT H^R g^TTI";

(qsT) sfOT ^jfe^lk 2 A qfrp " 5FTT- RR>"/ 3TPJ " ^ ^ ^ R f W f e TST " cjrfrfT *FT ĉTT.

3̂ cTT ^<mi4 :- fajpff/ ?<R: H ^ Q d / #31/ 3 1 ^ / 3 ^ (fTOF UJjftd <JT R31R eRTtf) ojjfti ^Tcdf^* 3TR> ^WRSRRT Hwftftfinfl) *f>r SIR 3frr <RT 3ftr 3*w &ftt $ tiiv (qfram £ #5TRR ajrg #r 5T?ir # sifd^dl ^ vufldH fc RT) I" (7T) ?icer "wefr ^T *m " ^ 3R ? R fc vm, Rz^RfSKT w anw, arafajnft^ift* ĉ r £r mtfft i)"

(iv) qftffTB- 11 #T ^T^TR RfstfotfiiR TM 5TKRT, atffRj- "qf^TF 12" JteiR«h <rfam £ *raftR â R m 3 ^ ^r 5*TT # SR^T ID ^diPch qfte^r $ w®K A R ^ ^ 5 ^r er?ir ^ gR^r ^ S I R ^ qfrerw * E*I%>

(2) ZiM* ^tlS^T T̂ ^ 1 ? R qftSTW ^ o2rf?p Wit J3R ?R #T ^TT 3̂ , ^HT £Sf^ RJOT 21 * S? (ST) % 3rtfR ^WNftiHlftd 3R5TR ^ t ^ r f t * 3n^T * 3R^fT * f a *T ^

(3) czrfar #7 ^TRSF q^wiT r̂ wffiJcT 3j?5 ^r ^rr ^ -w^ / 3 ^ r ^RRSRRY Hwff igR)^) R?OT 21 * a? (a) * 3tfr* ^iHR^it^d 3R^m ^ ^ ^ 3n^r * 3R T̂R 5R^r W ^ R *T P>5TT gRT 3frT fM*T ^R^T 5^1^ * Rjf^ft^ V&X <K 6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(i)]

(4) <?)c;iPi+ y f iwT ^r r̂afUcT siftf" ?u sjr^ % fpnr yfd+< f ^ s r ^ y # gt -n+di j?:- yfd+<;

(IT) -Hldl/fadl ^ - ^ i f a * M^WUI # 3TRT tt #T ^ R H ^ # W^f # | f STfd' ^ fpTCT ftcfaT yf?l<M I

(5) y i 4 U * m 3^wr wfcri^r fSr^r ^ < I I P I * y^anr #r f?rrr 3^r f?r ?nf?i^Ttr $ 3t%rf& W K * r t " f t ^ S T f ^mr yf^r^r # £ fatft wnrw ^r art?r T̂T 3 ^ ?frdT £ HY femi yfd<*>< y ^ w ^ W , 3TOTC[:- (3F) 3V^*|U|loH«b qT̂ U||J4| (qfMRTt) % ^^<A WW*;

(is) an^Rw 3? r̂rfSTor stif ^<iiP=h y f i ^m Mfo-mv;

(?T) a jspt fcr H ^ M K ^ r 3 M ^ R , S T H P I * + < I M K ^ yiiiloich ^ 3*TW yldPifa (g-) ji<r<3quiir<H<+1 qftorpr ^ 3mif3ftT f^rfocHT Tratfr ysrra- y ^ r ^ r # fa*Hdi;

(^) 3Î 3TVfeT <H4NU #^ 3Hld^+ 31RT ^ ^T 3T STT t̂ iUWcH ^ t &\$<bi H$<tS 3Trt3^nr #r g^m yfd^cH ysrra";

fpHT fM^T yfd+< I

(6) fomr yfd«M 3r apiaR ^ r ^t^nrr (3T) 3TS^f^ ?T3fr TOffc 3m" 3<yHJI%?f yfd^H SIE-TOft ^T ftqtt fSftPT 21 & S5 (S") & 3nftST TSIT Mft&iftd 3I^Tf?r yifttatit, yRJtol* 3JT JHW yfdPlf^T f̂ TH T̂ 3T îf^" yî ehiH £ ^ r t^P trflwr # 3 i^ fd yn^ # ^ 3ftr 3rraR 'HfJifd fSrtr̂ r 3it3R^ <HiiNu OFT ai^fltw 3î <ird f^iT B" *& y ^ ^ s " i i #T 3^err

(3) (i) 3j?q; # t̂stTr yfd^tf ^cwr n̂" yfRfTnT P ^ H I ^ K ^TT:

(̂ 7) f?)̂ rjT 21(13") ^ 3ItfR" 5T?JT qf^fTt^T 3i^7lf?1 yi f?l* l^ 5KT i f^ fT f̂T=T5T «Wfd 5 J ^ ^ g5RXT ^T 3IR^r T̂ feTTT 3m" Ml^+< # JTnr ^ y4lol<H >̂ fpfij JTW "̂ 35T yfTfRT ^ W t 3m" I ' ' " ' " T " • *"'*"*•'r ' 1 ' " " T 1 ^ " " - 1 ' • • «•• • • ' » « ' ' H . ! » » - • • • • - • — I i. . . — — . , - , - , . » w , , , , , u I . H » - I > - « « » I W » # » , „ , . „ [•m ii—w^ 3(i)] *irc<T >̂r w r e : sraraR^ 7 (H) nwW<f> ?rr ^rasr nfiPiRi, fvRP* arprf^i HTfSifcbi$t r̂ A<]Pm ^ tsm s> <Hidn g> fo^ arpir 3T%TTO gft aft ato 3 i ^ w *R*J g5t Tpfrr nfofcT *T5=TT ^ siq^t Rtffd ^ * P ^ fo^^i * 1*wra arraR r̂f*!f?r * aft? f^tasr ^rfcr * SICZHT g?r ft^m 21(H) g* amSt̂ iwwRmftd 3Pprf$r siiRtoril ĝ t atR ^ T ?R«n g> TFga g>t «rsf ^Rtem r̂erfcfir ftm "W t, fM£ g5t TJCP srict ^ 5 g5t *WR (T) arreR *rftfa 'jrg g5t *MR nRi<$a ^ ^ T TR * T * ^ f^^nn ^ ^rai aMt R<fr£ jrretag, m A3?# URIPI® ftRFt Jk;Fta> ttftapir <tailcM gR% * ftp? fom 21(a) ^ ar#r ^rawR^ifod arprf^r Hll&hlQ ^ 3FJ5TT 3rf5mF3cr 3*t aft, 3RI ?RTT fM*J JlfclSR, tfc ^ ^ <R 3Wft TOT *ffeT R ^ ^ t XTcF 5rfcT ^ qSt THRCTfc^cT q ^ T * ?tf % # H * ^ ? M * ?foR 3Tprf^ MlGkhtf ^ ^ 5 ^

(g) ^ g tft *i«fa wfct^r ^=TT gft R ^ gft ft^ir ^ftfa ^ m ^ f t ate ai^srf^t uift<M$l ^ i r f ^ 3rprf$r mfacPRt ^ %ftg> qffem tfgrfora W r ^ lenj 3rjsn Hra gSt ^ afR 3WR ?rf*rfcr gSt R<M tRfg^R^R'ft I r.

(^ Jteifto 'RteFT ^ ^rafter ^ gSt <J?TT ^ ft^ir r̂fti% Hi*ft«i* ^T ^ I * MRIPIRI f̂ Rf̂ r ift k̂iPw> TRlsm g> x̂TTePT * foUJ f̂ TĴ T 21 (a) * 3 ^ T ^ m R ^ d 3 1 ^ 5 ^ Hl(?)*l^ ^ 3iprT JTM ^ aft, g R I ^ r l 1 ^ ^ n % ^Tct Jtft'iflV! ^ TTST g5t Kft RHWIRfl^M I (^) 3T̂ 5Tf̂ r Ml^l^l ft^TW ^ftfct flSt RTOIR?ff 1? ft^R ^ T T 3tR ^ * ^>R«I ^T 3TWRfT ĝ TTT 5tR v l̂T % 3PTfeT T̂ 3TT Î TTTRcT W&V 1 (ej ^iPicb t̂ t̂ pjT r̂ m$ft ^ g?t ^?n 3 a^siffi mftr*î 1 M^sr ^ftf^r <& R^mfM ^R ft^R CIR^ g> q?gM m ^ ^ ^ ^r ^rgji jrfafafa, ftRT^ ^ ai^rf^f mft*i^ % ^ i P i * ^ t w r WEITIORT W r * raif ai^ar'stPmra ^ aft, ^RT ^R?I feq w^ T̂ct irfc^R gft T M g>r RRwii ^ I T 3tk * nfo^d q^n g>t Rtfri MTO gR% g> ̂ r IRT g> ift?R ^ r 3n^i T̂RET g^nr ^ aTra r̂a? ^r^r'amj l

(ii) Tjrg r̂ 1*FI ^WR ufd$<H 'Eî naft ^ imcff 5̂t P I H I ^ K w^r 5̂t ^iwft :

(gs) jrrat^cp ^i ^ W T urai^Ki. f̂ R t̂ # <̂iiP>» qffem >H îl̂ id w r * raT? ar^irf^r snf^Rt ^ arjw arfimTO g?t aft 31R ap% ĝ> wm fo**\m $ iwra ^T^R Hl?l«|yci ^WT ^ t ar^ft fMiet g?r PTZR 21 (ia) r̂ iraiMRHil̂ d arpff^T wifira^, aî rer, arraR ^ftfo afr? ^ r ?̂R«IT ^ JT>J?I g^, yt5i q^tsm ^x||f^d fo*TT TWT t , ^ R Mld^cl ^TT ^ * ^ 1 ^ ^ 3 ? faff * *ft?R ^ f ^ T ^PTT I (H) airaR f̂*rfcr Ttift? Hfcfrd tr^T TR a i ^ R«te ?rRra> ft?^w * "?rm fMf^ jrfcre ;̂ ^ ^ r t FT, wft H H W m ^ ) ^ HfclRI^ gRT ^ T T faOT umTTT q7 a^rft ^T f̂f%̂T f̂ Rf̂ * ^ i f ^ V^W ^rfeicT gR^ * raij f^nr 21(H) g> 3i*T TWiuRniftd arprf^i wifitertr r̂ 3i^n 3T%rra^aft, f^M g?t Tjg? f̂t% ^ 5 g5t ' H R yk%>& ^I^TT * r̂% r̂ fggfar *et^? M ^ f̂tcR fate *ftfa £ , (̂ T) ai^srf^r mfocHl) «ri?T ^ w i g?r ara^Roi gR^n aft? wroiww* an^i ^TR^ ^ W t 3Tpi^r grfergjR) * w ^ t w<iw<t> wm\ ^ j « # ^ ^ft.-n»fR Hfd<̂<H ^r^naft ^ vsrra gR% ^ Icn?

ijcp ?g^f M w ?<ftfa g?T TTOT cfR̂ r gjT ftg^q ^rm vsff «rf!f * g5Rq gjr WT c ^ r $ rarj 3fR ^iPlcb q%ur ?T TTifeT «rfcT qSt cRTT if H|4>MI0> ^ ^ W T HldPlRl ^Rf^f ^ % r f ^ P ^ « M >̂T Tf̂ rcR gR r̂ * fenr f ^ 21{H) A ««imR*<iftd aiprl^ wfopRt ^ a?g§n JIRT g5t aft, BRT ^t^ra (U) ^felFfoj ^ O T T) iWfiRf «Tfct flSt ^ T *f 31^tRr HlBlchl̂ HT#*R ^T ^ t l ^ HfllPtfir, f^f^ * arp[Rf mlSicbî ^ J>«4iPi«*> *Rter°r ?raifecT g> r̂ * fen? 3?pn 3itora gSt aft, SRI f̂Rfr ftq «n% gieT JfflrgR^ 'iraT ĝT ftPRgU WtW aft? :,t4R i r fc t^ TTS^ gft Rq^HRTgR% g> ^ T TRI^ ' f t tR ^ arr^ qrf^ gRnr # arrawgj ?m^ y^j I 8 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(i)] ofojire <jSr sft fore 21(a) * aitfto ^wwRwftd at^sfit jnf£ra>r$T * arr&r * ST^BR W r ^ î tam ^ ^W8RI sifcr TIT ̂ 5 <#) ?̂rr M ^ 3r£?r <rft Trrfa * tftar f^fr * iftrc jrfcr^ gsr w r CPW I [TR tf. W ~ l 1014/6/2011 -̂ tH '̂cHJjHl] 3T^I ^ . *F5T, TTĝ T TTR^ ftoM-ijcf RPKIH *TRCT £ *TuTTr=r % arfipqw tf. tmotfo w 28-10/45-^ (1) Brfoi 21 Qwi.

1945 gRt n<r»Rm f ^ T ^ ST 3TT* ^WT 3?fcR TOffcH STf^^TT ^ . msPT.fa.' 844(3?) ^m 26-11-2012 WH fo*TT ̂ RT err I MINISTRY OF HEALTH AND FAMILY WELFARE (Department of Health) NOTIFICATION New Delhi, the 30th January, 2013 r GLS.R. 53(E).— Whereas a draft of certain rules further to amend the Drugs and Cosmetics Rules, 1945, was published, as required by section 12 read with section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), vide notification of the Government of India, Ministry of Health and Family Welfare (Department of Health), number G.S.R.

821(E), dated the 18th November, 2011, in the Gazette of India, Extraordinary, Part II, section 3, sub-section (i), dated the 18th November 2011, inviting objections and suggestions from ail persons likely to be affected thereby before the expiry of a period of forty five days from the date on which the copies of the Official Gazette of the said notification were made available to the public;

And whereas copies of the Gazette were made available to the public on the 24th November, 2011; • And whereas, objections and suggestions received from the public on the said rules have been considered by the Central Government;

Now, therefore, in exercise of the powers conferred by sectionsv12 and 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government, after consultation with the Drugs Technical Advisory Board, hereby makes the following rules further to amend the Drugs and Cosmetics Rules, 1945, namely: -

1. (1) These rules may be called the Drugs and Cosmetics (First Amendment) Rules, 2013.

(2)They shall come into force on the date of their publication in the Official Gazette.

I HHtdt*' • HiHI . IMI . H | . H1»ll|Ht=> I • II"i-Mil • « I I) ^. ILIHU.., , .M i fW l> > • • • • • « | M » «!* * • * I* '* Hill l l l |Mf*MHMIH'*W* «•!

[W\ ll—wm 3(i)j «IM ^1 WT* : amifclK"! 9

2. In the Drugs and Cosmetics Rules, 1945, (hereinafter referred to as the said rules),-

(i) after rule 122DAA, the following rule shall be inserted, namely:- "122-DAB- Compensation in case of injury or death during clinical trial.-

(1) In the case of an injury occurring to the clinical trial subject, he or she shall be given free medical management as long as required.

(2) In case the injury occurring to the trial subject is related to the clinical trial, such subject shall also be entitled for financial compensation as per order of the Licensing Authority defined under clause (b) of rule 21, and the financial compensation will be over and above any expenses incurred on the medical management of the subject.

(3) In the case of clinical trial related death of the subject, his/her nominee(s) would be entitled for financial compensation, as per the order of the Licensing Authority defined under clause (b) of rule 21, and the financial compensation will be over and above any expenses incurred on the medical management of such subject.

(4) The expenses on medical management and financial compensation in the case of clinical trial injury or death of the trial subject shall be borne by the sponsor of trie clinical trial.

(5) Any injury or death of the subject occurring in clinical trial due to following reasons shall be considered as clinical trial related injury or death and the subject or his/her nominee(s), as the case may be, are entitled for financial compensation for such injury or death:

(a) adverse effect of investigational product(s);

(b) violation of the approved protocol, scientific misconduct or negligence by the Sponsor or his representative or the investigator;

(d) use of placebo in a placebo-controlled trial;

(e) adverse effects due to concomitant medication excluding standard care, necessitated as part of approved protocol;

(f) for injury to a child in-utero because of the participation of parent in clinical trial;

(g) any clinical trial procedures involved in the study.

(6) The Sponsor, whether a pharmaceutical company or an institution shall give an undertaking along with the application for clinical trial permission to the Licensing Authority defined in clause (b) of Rule 21, to provide l\\"\ QT^'h-'y 10 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(i)] compensation in the case of clinical trial related injury or death for which subjects are entitled to compensation.

(7) In case the Sponsor fails to provide medical management for the injury to the subject and / or financial compensation to the trial subject for clinical trial related injury or financial compensation to the subject's nominee(s) in case of clinical trial related death of the subject, the Licensing Authority may after giving an opportunity to show cause why such an order should not be passed, by an order in writing, stating the reasons thereof, suspend or cancel the clinical trial and / or restrict Sponsor including his representative(s) to conduct any further clinical trials in the country or take any other action deemed fit under the rules.

(ii) in the said rules, in Schedule Y, in paragraph 2 relating to Clinical Trial,

(a) in sub paragraph (2) relating to Responsibilities of Sponsor,-

(i) clause (iv) shall be substituted with the following, namely:- "(iv) Any report of serious adverse event of death occurring in clinical trial, after due analysis shall be forwarded by the Sponsor to Chairman of the Ethics Committee and Chairman of the Expert Committee constituted by the Licensing Authority as defined under rule 21(b) under Appendix XII with a copy of the report to the Licensing Authority and the head of the Institution where the trial has been conducted within ten calendar days of occurrence of the serious adverse event of death. The report of the serious adverse event other than death, after due analysis, shall be forwarded by the Sponsor to the Licensing Authority, Chairman of the Ethics Committee and the head of the Institution where the trial has been conducted within ten calendar days of occurrence of the serious adverse event.";

(b) after clause (iv), the following shall be inserted, namely:- "(v) in case of injury or death occurring to the clinical trial subject, the Sponsor (whether a pharmaceutical company or an Institution) or his representative, whosoever had obtained permission from the Licensing Authority for conduct of the clinical trial, shall make payment for medical management of the subject and also provide financial compensation for the clinical trial related injury or death in the manner as prescribed in Appendix XII;

(vi) the Sponsor (whether a pharmaceutical company or an Institution) or his representative, whosoever had obtained permission from the Licensing Authority for conduct of the clinical trial, shall submit details of compensation provided or paid for [*TPT II_^TJ5 3( i ) ] qR(T ^)I TT̂ RJf : STOWl^?

clinical trial related injury or death, to the Licensing Authprity within thirty days of the receipt of the order of the Licensing Authority.";

(i) the sub paragraph "(3)" shall be numbered as "(3)(i)";

(ii) in the so numbered, clause (i), the words and figures "Sponsor Within 24 hours and to the Ethics Committee that accorded approval to the study protocol within 7 working days of their occurrence" shall be substituted with the words, figures and brackets "Licensing Authority defined under clause <b) of rule 21, the Sponsor or his representative, whosoever had obtained permission from the Licensing Authority for conduct of the clinical trial, and the Ethics Committee that accorded approval to the study protocol, within twenty four hours of their occurrence. The report of the serious adverse event of death, after due analysis shall be fprwarded by the Investigator to Chairman of the Ethics Committee and Chairman of the Expert Committee constituted by the Licensing Authority under Appendix XII with a copy of the report to the Licensing Authority and the head of the Institution where the trial has been conducted within ten calendar days of occurrence of the serious adverse event of death. The report of the serious adverse event other than death, after due analysis shall be forwarded to the Licensing Authority, Chairman of the Ethics Committee and the head of the Institution where the trial has been conducted within ten calendar days of occurrence of the serious adverse event.";

(iii)after the so numbered clause (i), the following clause shall be inserted, namely:- "(ii) The Investigator shall provide information to the clinical trial subject through informed consent process as provided in Appendix V about the essential elements of the clinical trial and the subject's right to claim compensation in case of trial related injury or death. He shall also inform the subject or his / her nominee(s) of their rights to contact the Sponsor or his representative whosoever had obtained permission from the Licensing Authority for conduct of the clinical trial for the purpose of making claims in the case of trial related injury or death.";

(d) in clause (5) relating to Responsibilities of the Ethics Committee, after sub-clause (iii), the following sub-clause shall be inserted, namely:- "(iv) In case of serious adverse event of death occurring to the clinical trial subject, the Ethics Committee shall forward it's report on the serious adverse event of death, after due analysis, along with its opinion on the financial compensation, if any, to be paid by the 12 THE GAZETTE OF INDIA : EXTRAORDINARY [PART H—SEC. 3(i)] Sponsor or his representative, whosoever had obtained permission from the Licensing Authority as defined under rule 21(b) for conducting the clinical trial, to the Chairman of the Expert Committee constituted by the Licensing Authority under Appendix XII with a copy of the report to the Licensing Authority within twenty one calendar days of the occurrence of the serious adverse event of death. In case of serious adverse event, other than death occurring to the clinical trial subject, the Ethics Committee shall forward its report on the serious adverse event after due analysis along with its opinion on the financial compensation, if any, to be paid by the Sponsor or his representative, whosoever had obtained permission from the Licensing Authority for conducting the clinical trial, to the Licensing Authority within twenty one calendar days of the occurrence of the serious adverse event."

(e) after sub paragraph (5), the following shall be inserted namely:- "5(A). Serious Adverse Events

(1) A serious adverse event is an untoward medical occurrence during clinical trial that is associated with death , in patient hospitalisation (in case the study was being conducted on out-patient), prolongation of hospitalisation (in case the study was being conducted on in-patient), persistent or significant disability or incapacity, a congenital anomaly or birth defect or is otherwise life threatening.

(2) The Investigator shall report all serious and unexpected adverse events to the Licensing Authority as defined under clause (b) of rule 21, the Sponsor or his representative, whosoever had obtained permission from the Licensing Authority for conduct of the clinical trial, and the Ethics Committee that accorded approval to the study protocol, within twenty four hours of their occurrence as per Appendix XI, and the said Licensing Authority shall determine the cause of injury or death as pei; the procedure prescribed under Appendix XII and pass orders as deemed necessary.".

(iii) in APPENDIX V, (A) in serial number 1, in sub serial number 1.1, the entries against item number 9 shall be substituted with the following, namely:- "9. Statement describing the financial compensation and medical management as under:

[W\ II—W^ 3(i)] *m *K7 TFm : STOWR"! 13

(a) In the event of an injury occurring to the clinical trial subject, such subject shall be provided free medical management as long as required.

(b) In the event of a trial related injury or death, the Sponsor or his representative, whosoever has obtained permission from the Licensing Authority for conduct of the clinical trial, shall provide financial compensation for the injury or death.";

<B) in serial number 2, after the line "Date of Birth / Age " the following shall be inserted, namely: - "Address of the Subject Qualification Occupation: Student / Self-Employed / Service / Housewife / Others (Please tick as appropriate) Annual Income of the subject '• Name and address of the nominee(s) and his relation to the subject (for the purpose of compensation in case of trial related death).";

(C) after the words, "Name of the witness " occurring at the end, the following shall be inserted, namely:- "(Copy of the Patient Information Sheet and duly filled Informed Consent Form shall be handed over to the subject or his / her attendant).";

(iv) after APPENDIX XI, the following shall be inserted, namely: - "APPENDIXXH Compensation in case of injury or death during clinical trial

(1) In the case of an injury occurring to the clinical trial subject, he or she shall be given free medical management as long as required.

(3) In the case of clinical trial related death of the subject, his/her nominee(s) would be entitled for financial compensation, as per the order of the Licensing Authority defined under clause (b) of rule 21, and the financial \\\<\ GnrlO-M 14 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(i)] compensation will be over and above any expenses incurred on the medical management of the subject.

(4) The financial compensation for clinical trial related injury or death could be in the form of:-

(a) payment for medical management;

(b) financial compensation for trial related injury;

(d) financial compensation for the child injured in-utero because of the participation of parent in clinical trial.

(5) The Sponsor or his representative, whosoever had obtained permission from the Licensing Authority for conduct of the clinical trial, shall provide financial compensation, if the injury or death has occurred because of any of the following reasons, namely: -

(a) adverse effect of investigational product(s);

(b) any clinical trial procedures involved in the study;

(c) violation of the approved protocol, scientific misconduct or negligence by the Sponsor or his representative or the Investigator;

(d) failure of investigational product to provide intended therapeutic effect;

(e) use of placebo in a placebo-controlled trial;

(f) adverse effects due to concomitant medication excluding standard care, necessitated as part of approved protocol;

(g) injury to the child in-utero because of the participation of parent in clinical trial.

(6) Procedure for payment of financial compensation

(a) The Investigator shall report all serious and unexpected adverse events to the Licensing Authority as defined under clause (b) of rule 21, the Sponsor or his representative whosoever had obtained permission from the Licensing Authority for conduct of the clinical trial and the Ethics Committer t̂hat accorded approval to the study protocol, within twenty four hours of their occurrence as per Appendix XI.

(b) (i) The cases of serious adverse events of death shall be examined as under:

(A) An independent Expert Committee shall be constituted by the Licensing Authority as defined under rule 21(b) to examine the cases and recommend to the Licensing Authority for the purpose of arriving at the cause of death [qpHI—TgF5 3(i)] qR?l ^T ^ r a ^ : 3TC11WT 15 and quantum of compensation in case of clinical trial related death.

(B) The Sponsor or his representative, whosoever had obtained permission from the Licensing Authority for conducting the clinical trial, and the Investigator shall forward their reports on serious adverse event of death after due analysis to Chairman of the Ethics Committee and Chairman of the Expert Committee with a copy of the report to the Licensing Authority as defined under rule 21(b) and the head of the Institution where the trial has been conducted, within ten calendar days of occurrence of the serious adverse event of death.

(C) The Ethics Committee shall forward its report on serious adverse event of death after due analysis along with its opinion on the financial compensation, if any, to be paid by the Sponsor or his representative, 'whosoever had obtained permission from the Licensing Authority as defined under rule 21(b) for conducting the clinical trial, to the Chairman of the Expert Committee with a copy of the report to the Licensing Authority within twenty one calendar days of the occurrence of the serious adverse event of death.

(D)The Expert Committee shall examine the report of serious adverse event of death and give its recommendations to the Licensing Authority for the purpose of arriving at the cause of the adverse event within thirty days of receiving the report from the Ethics Committee, and the Expert Committee while examining the event, may take into consideration, the reports of the Investigator, Sponsor or his representative whosoever had obtained permission from the Licensing Authority for conducting the clinical trial and the Ethics Committee.

(E)ln the case of clinical trial related death, the Expert Committee shall also recommend the quantum of compensation to be paid by the Sponsor or his representative, whosoever had obtained permission from the Licensing Authority as defined under rule 21(b) for conducting the clinical trial.

m«i &,Tli3-$- 16 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(i)] (F) The Licensing Authority shall consider the recommendations of the Expert Committee and shall determine the cause of death and pass orders as deemed necessary.

(G) In case of clinical trial related death, the Licensing Authority, after considering the recommendations of the Expert Committee, shall decide the quantum of compensation to be paid by the Sponsor or his representative, whosoever had obtained permission from the Licensing Authority for conducting the clinical trial and shall pass orders as deemed necessary within three months of receiving the report of the serious adverse event.

(ii) Cases of serious adverse events, other than deaths, shall be examined as under:

(A) The Sponsor or his representative, whosoever had obtained permission from the Licensing Authority for conducting the clinical trial, and the Investigator shall forward their reports on serious adverse event, after due analysis, to the Licensing Authority as defined under rule 21(b), Chairman of the Ethics Committee and the head of the Institution where the trial has been conducted within ten calendar days of occurrence of the serious adverse event.

(B) The Ethics Committee shall forward its report on the serious adverse event, after due analysis, along with its opinion regarding the financial compensation, if any, to be paid by the Sponsor or his representative, whosoever had obtained permission from the Licensing Authority as defined under rule 21(b) for conducting the clinical trial, to the Licensing Authority within twenty one calendar days of occurrence of the serious adverse event.

(C)The Licensing Authority shall determine the* cause of injury and pass order as deemed necessary. The Licensing Authority shall have the option to constitute an independent Expert Committee, wherever considered necessary, to examine such serious adverse events of injury, which will recommend to the Licensing Authority for arriving at the cause of the injury and also the quantum of [•qui ii—-@n>5 3(0] ms ^ i T&m : 3WIHK"I 17 compensation in case of clinical trial related injury, to be paid by the Sponsor or his representative whosoever had obtained permission from the Licensing Authority as defined under rule 21(b) for conducting the clinical trial.

(D) In case of clinical trial related injury, the Licensing Authority, shall decide the quantum of compensation to be paid by the Sponsor or his representative whosoever had obtained permission from the Licensing Authority for conducting the clinical trial, and shall pass orders as deemed necessary within three months of receiving the report of the serious adverse event.

(c)The Sponsor or his representative, whosoever had obtained permission from the Licensing Authority for conducting the clinical trial, shall pay the compensation in case of clinical trial -related injury or death as per the order of the Licensing Authority as defined under rule 21 (b) within thirty days of the receipt of such order.

[F. No. X-11014/6/2011-DFQC] ARUN K. PANDA, Jt. Secy.

SS'S G^B-KWS»*"« amended vide notification number G.S.R. 844(E), dated the 26th November, 2012.

Insertion of Rule 122DAB, Appendix XII_Death Compensation_Section

The enactment

Full text

Find the provision, not just read it